These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33552465)

  • 21. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
    Siamashvili M; Davis SN
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1081-1089. PubMed ID: 34015974
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Pratley RE
    Medscape J Med; 2008 Jul; 10(7):171. PubMed ID: 18769687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment.
    Xing C; Zhang J; Zhao H; He B
    Int J Womens Health; 2022; 14():91-105. PubMed ID: 35140526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.
    Szczesnowicz A; Szeliga A; Niwczyk O; Bala G; Meczekalski B
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
    Davidson JA
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention.
    Xiong C; Wu J; Ma Y; Li N; Wang X; Li Y; Ding X
    Diabetes Metab Syndr Obes; 2024; 17():865-880. PubMed ID: 38406269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
    Xing C; Li C; He B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):2950-63. PubMed ID: 32490533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.
    Li L; Feng Q; Ye M; He Y; Yao A; Shi K
    J Obstet Gynaecol; 2017 Nov; 37(8):1036-1047. PubMed ID: 28657375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.
    Lamos EM; Malek R; Davis SN
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):401-408. PubMed ID: 28276778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
    Kendall DM; Kim D; Maggs D
    Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
    Bjekić-Macut J; Vukašin T; Velija-Ašimi Z; Bureković A; Zdravković M; Andrić Z; Branković M; Crevar-Marinović S; Madić T; Stanojlović O; Milutinović DV; Livadas S; Mastorakos G
    Curr Pharm Des; 2021; 27(36):3812-3820. PubMed ID: 33463457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.